Loading
Led RATIFY, the trial that made midostaurin the first targeted therapy added to induction chemotherapy for AML.
Richard Stone was principal investigator of RATIFY (CALGB 10603), the international trial showing midostaurin added to standard chemotherapy improves survival in FLT3-mutant AML, the first new approval in AML induction in 40 years and the first targeted therapy in the disease. He chaired the Alliance leukaemia committee and has led trials across AML, including gemtuzumab and quizartinib studies.
Shares QuANTUM-First, RATIFY (CALGB 10603), QuANTUM-First: quizartinib added to intensive chemotherapy and continued as maintenance in newly diagnosed FLT3-ITD AML, FLT3.
Shares FLT3, Acute myeloid leukaemia, Small-molecule kinase inhibitors and the tags aml, flt3.
Shares RATIFY (CALGB 10603), FLT3, Acute myeloid leukaemia.
Shares FLT3, Acute myeloid leukaemia and the tag aml.
Shares FLT3, Acute myeloid leukaemia and the tag flt3.
Shares Acute myeloid leukaemia and the tag cooperative-group.
Shares Acute myeloid leukaemia and the tag cooperative-group.
Shares FLT3, Acute myeloid leukaemia, Small-molecule kinase inhibitors.